A Phase III Randomized Trial of Eribulin (E) with Gemcitabine (G) Vs Standard of Care (SOC) for Patients (pts) with Metastatic Urothelial Carcinoma (muc) Refractory to or Ineligible for PD/PDL1 Antibody (ab): SWOG S1937 Updated Design.
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要